ScreenerHero

IKTINIktinos Hellas S.A. Greek Marble Industry Technical and Touristic Company

ATH · GR · Industrials · Building Products & Equipment · iktinos.gr
0.3270EUR-0.46%Mkt Cap: 40.46M $P/E: —

Iktinos Hellas S.A. Greek Marble Industry Technical and Touristic Company engages in the mining, processing, and trading of marbles and granites, and other decorative materials in Greek Territory, the Eurozone, and inter…

Industry Peers

Building Products & Equipment
Screen all
TT
Trane Technologies plc
$99.77BUSDP/E 33.8
JCI
Johnson Controls International plc
$86.65BUSDP/E 40.3
CARR
Carrier Global Corp.
$50.14BUSDP/E 43.1
SGO
Compagnie de Saint-Gobain S.A.
$43.21BUSDP/E 15.1
GEBNE
Geberit AG
$22.22BUSDP/E 32.3
GEBN
Geberit AG
$21.81BUSDP/E 32.1
KRX
Kingspan Group plc
$19.68BUSDP/E 26.8
LXI
LENNOX INTL INC. DL-,01
$14.24BUSDP/E 19.5
CSL
Carlisle Companies Incorporated
$14.60BUSDP/E 20.9
MAS
Masco Corporation
$14.45BUSDP/E 16.9
LII
Lennox International Inc.
$13.92BUSDP/E 17.9
MAIR
Madison Air Solutions Corporation Class A Common Stock
$13.04BUSDP/E 60.4
BEAN
BELIMO Holding AG
$11.73BUSDP/E 50.0
OC
Owens Corning
$11.70BUSD
WMS
Advanced Drainage Systems, Inc.
$10.84BUSDP/E 24.5
SPXC
SPX Corporation
$10.38BUSDP/E 36.5
NIBE-B
NIBE Industrier AB Class B
$8.10BUSDP/E 35.3
BLDR
Builders FirstSource, Inc.
$7.55BUSDP/E 76.3
AWI
Armstrong World Industries, Inc.
$7.55BUSDP/E 24.5
ROCK-A
ROCKWOOL International A/S
$6.47BUSD
HeadlineSourceTime
Older
Heineken’s Strongbow adds NaviLens levels to packaging

The cider brand has added a high-contrast NaviLens QR code to its cans.

Packaging Gateway
3 firms to lay off hundreds of North Jersey-based employees

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

The Bergen Record
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters